To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent ...

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of ...

Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new ...

Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environmentCAMBRIDGE, Mass., May 02, ...

Viehbacher's pay that year was exceeded only by Jason Robins, the CEO of DraftKings, and Douglas Ingram, president and chief executive of a smaller biotech, Sarepta Therapeutics (Nasdaq: SRPT). But ...

Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

Biogen shares gained ground before market open Wednesday, after the company reported first-quarter profit that beat analysts’ ...

While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large ...

In its first quarter, Biogen took in $2.29 billion in revenue, which was down by 7% on a year-over-year basis. Its product ...

Biogen beat Wall Street estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset ...

Biogen on Wednesday exceeded analyst profit estimates for the first quarter of 2024 as the biotech’s cost-cutting measures ...